http://www.fiercepharma.com/story/gilead-litigation-says-claims-merck-abbvie-sovaldi-are-patently-wrong/2014-07-21
... There is litigation involving Gilead ($GILD) and AbbVie ($ABBV), Merck ($MRK) and Idenix Pharmaceuticals ($IDIX) which Merck is buying. All three are developing their own hep C contenders. There is also a lawsuit from Roche ($RHHBY). The lawsuits represent the kinds of patent litigation more often seen in the high-tech industry than in pharma, where patent fights to stop generic products are more common, The Wall Street Journal asserts. ...
... In one lawsuit, Merck is accused of demanding a 10% share of Sovaldi sales in exchange for use of two Merck patents. Cambridge, MA-based Idenix filed suits against Gilead in France, Germany and the U.K. on grounds that the company infringed a recently granted European patent on nucleosides, as well as filing suit in the U.S. ...
... In the litigation involving AbbVie, that company says it has patented the process of combining two of Gilead's drugs--Sovaldi and an experimental drug called ledipasvir, which Gilead plans to combine into one treatment. While AbbVie doesn't have an ownership claim to the drugs, it is legal for companies to get patents for the "method of use" for products they don't own ...
... Gilead ... claims in litigation, that AbbVie and its former parent Abbott Laboratories ($ABT) conducted a "fraudulent scheme" to get the patents for the methods that it and Pharmasset developed for treating hepatitis C ...
Related Articles:
Merck demand triggers expanding patent war over Gilead's sofosbuvir
Gilead's hot-selling Sovaldi draws more patent attacks
Merck snatches Idenix for $3.8B as it watches Sovaldi gobble up market share
Shunned Gilead/Bristol-Myers hep C combo may be too good for docs to ignore
AbbVie readies production in anticipation of hep C treatment approval
@RonWyden @ElizabethWarren @HillaryClinton @NAACP @SEIU @Teamsters @AFLCIO @HepC @HCV @Liber8 @Gilead
No comments:
Post a Comment